Bill S-201 Could Reshape Sickle Cell Care in Canada — Here’s What It Would Do

More than 6,500 Canadians live with sickle cell disease, and by most accounts, that number understates the real total. Despite this, Canada has no national standard for how the disease is diagnosed, treated, or tracked — something Bill S-201 is designed to change.

Introduced in the Senate in November 2023 by the Honourable Marie-Françoise Mégie and now advancing after passing second reading in June 2024, the bill would establish a national research network and patient registry, set consistent diagnostic and treatment standards across provinces, improve training for healthcare professionals, and guarantee universal newborn screening — something most, but not all, provinces and territories currently provide.

Where the push came from

The push behind the bill grew out of a collaboration between the Sickle Cell Disease Association of Canada (SCDAC) and the University of Ottawa’s Interdisciplinary Centre for Black Health, after SCDAC president Biba Tinga raised a simple but pointed question: how could a research centre focused on Black health not mention sickle cell disease at all? That conversation, beginning in 2021, led to a joint awareness event, a Senate breakfast on the issue, and ultimately the bill itself.

Dr. Ewurabena Simpson, a hematologist at CHEO and professor at the University of Ottawa, has pointed out that while the U.S. and parts of Europe have moved faster on sickle cell care, new therapies in Canada are often stalled by lengthy approval processes and a shortage of specialists. Even hydroxyurea — a decades-old, well-established medication with proven benefits for SCD — is still used off-label in Canada rather than formally approved, largely because the domestic patient population is considered too small to justify the regulatory investment.

For patients and families, the gaps show up as everyday realities: choosing hospitals based on which one understands the disease, restructuring careers and travel around access to care, and navigating stigma in emergency rooms that too often treat pain crises with suspicion rather than urgency.

Bill S-201 won’t fix all of that on its own. But advocates see it as the first real step toward the kind of coordinated national response that sickle cell disease has been missing in Canada for decades.